BNET Industries
Conceptus Inc. (CPTS) is in the Health Care Industry
- Revenue
- Dec 31 2007
- $64.4M
- Profit
- Dec 31 2007
- ($11.6M)
- Market Cap
- Sep 04 2008
- $494.4M
Latest News and Analysis
Conceptus, Inc. Q2 2008 Earnings Call Transcript
Conceptus Inc. CPTS Q2 2008 Earnings Conference Call
Conceptus, Inc. Q1 2008 Earnings Call Transcript
Conceptus, Inc. Q1 2008 Earnings Call Transcript
Conceptus Inc. Q4 2007 Earnings Call Transcript
Conceptus Inc. Q4 2007 Earnings Call Transcript
Additional Resources
Conceptus to Present at the Morgan Stanley Global Healthcare Unplugged Conference
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ: CPTS) announced today that Mark Sieczkarek, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, at 3:20 p.m. EDT. The conference will be held at the Grand Hyatt New York Hotel. ...
Understand Obstetric & Gynecology Trends in the Use of Birth Control Devices
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/c8be28/contraceptive_devi) has announced the addition of the "Contraceptive Devices: Where Are They Now? - Understanding Obstetric & Gynecology Trends in the Use of Birth Control Devices" report to their offering. This report encapsulates the current and expected trends of Ob/Gyn surgeons use...
A Comparative Analysis of Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4643be/contraceptive_devi) has announced the addition of the "Contraceptive Devices: Improving Professional Education Events for Ob/Gyn's Specializing in Birth Control Procedures" report to their offering. This report compares Ob/Gyn surgeons experience with and perceptions of professional education events from the following companies: Barr...
Conceptus Reports Sharply Higher Second Quarter Net Sales of $25.7 Million
Generates $3 Million Positive Cash Flow in the Quarter Revises 2008 Net Income Guidance MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today reported financial results for the three and six...
Conceptus to Present at the 7th Annual Needham & Company Biotechnology and Medical Technology Conference
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS) announces that Mark Sieczkarek, president and chief executive officer, will present at the Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 11, at 9:30 a.m. EDT. The conference will be held at The New York Palace Hotel from June 11...
Essure Procedure Now Covered by Medicaid in California
MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- Conceptus, Inc. developer of the EssureR procedure, the first and only non-incisional permanent birth control method available, today reported that Medi-Cal, California's state fee-for-service Medicaid program, is now covering the Essure procedure. Low-income or disabled women in California now have...
Conceptus to Present at the 7th Annual JMP Securities Research Conference
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS) announces that Mark Sieczkarek, president and chief executive officer, will present at the JMP Securities Research Conference on Tuesday, May 20, at 2:30 p.m. PDT. The conference will be held at The Ritz-Carlton in San Francisco, California from May 19 - May 21,...
Essure Procedure Now Covered by Medicaid in California
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq: CPTS) developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today reported that Medi-Cal, California's state fee-for-service Medicaid program, is now covering the Essure procedure. Low-income or disabled women in California now have a safe and effective...
Conceptus Reports First Quarter Net Sales Up 53%
Reaffirms 2008 Net Sales and Net Income Guidance MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today reported financial results for the three months ended March 31, 2008. Net sales for the...
Conceptus to Hold 2008 First Quarter Financial Results Conference Call May 6, 2008
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today announced that the Company will release 2008 first quarter financial results on Tuesday, May 6, 2008 after the close of market. Management will host an investment...
Conceptus to Present at the Cowen and Company's 28th Annual Health Care Conference
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS) announces that Mark Sieczkarek, president and chief executive officer, will present at the Cowen and Company's 28th Annual Health Care Conference on Monday, March 17, at 3:15 p.m. EST. The conference will be held at the Boston Marriot Copley Place Hotel in Boston,...
Conceptus Hires Todd Sloan as Vice President of Marketing
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq: CPTS) announced that Todd Sloan joined the Company today as Vice President of Strategic and Professional Marketing, reporting to Mark Sieczkarek, President and Chief Executive Officer. Mr. Sloan is responsible for the Company's strategy process, coordinating and implementing the business development plan and...
Conceptus to Present at the Raymond James 29th Annual Institutional Investors Conference
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (NASDAQ:CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, announces that Mark Sieczkarek, president and chief executive officer, will present at the Raymond James 29th Annual Institutional Investors Conference on Tuesday, March 4, at 1:05 p.m. EST....
Conceptus Reports Fourth Quarter Financial Results
In-Office Procedures Continue to Drive Growth MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today reported financial results for the three and 12 months ended December 31, 2007. Net sales for...
Conceptus to Hold 2007 Fourth Quarter Financial Results Conference Call February 19, 2008
MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today announced that the Company will release 2007 fourth quarter financial results on Tuesday, February 19, 2008 after the close of market. Management will host an investment community...
Low Birth Weight and Allergy: Possible Pleiotropic Effect of ACP1
Abstract The well-known relationship between low birth weight and allergies prompted us to investigate a possible pleiotropic effect of ACP1 on these conditions. ACP1 is a polymorphic enzyme that affects signal transduction of insulin and other growth factors, T-cell receptor signaling, and the regulation of flavoenzyme activity. Our...
Conceptus Introduces 2008 Financial Guidance, Updates 2007 Guidance
Acquires European Distributor and Begins U.S. Advertising Campaign Conference Call Begins at 4:30 p.m. Eastern Time Today MOUNTAIN VIEW, Calif. -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure[R] procedure, the first and only non-incisional permanent birth control method available, today updated financial guidance for the fourth...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View Related Content by Tag Close
- Incorporated: 1992
- CEO: Mr. Mark M. Sieczkarek
- Employees: 214
Conceptus is engaged in the development, manufacturing and marketing of the Essure® permanent birth control system, a medical device for women and a form of contraception worldwide. The Essure device is a proprietary micro-insert designed to be deployed permanently into each fallopian tube using its minimally invasive transcervical tubal access catheter system. The Essure procedure is typically performed as an outpatient procedure. As of Jan 30 2008, Co. had 20 published U.S. patent applications, 26 U.S. issued patents, and 29 foreign and/or international patent applications pending and 61 issued foreign patents.
Key Competitors
Conceptus Inc. Company Info
Board of Directors
Ms. Kathryn A. Tunstall
Chairman
Mr. Mark M. Sieczkarek
Mr. Michael A. Baker
Mr. Thomas F. Bonadio
Mr. Robert V. Toni
Mr. Peter L. Wilson
Contact Information
1021 Howard Avenue
San Carlos, CA
650 802-7240